Drugs / PICX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07715630 | Jul 2026 → Apr 2028 expected | refractory plasma cell neoplasm | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PICX | “It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the...” NCT07715630 ↗ |
| Known as | PICX Injection | “It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the...” NCT07715630 ↗ |
| Modality | Cell therapy | “PICX Injection, an in vivo prepared CAR-T cell therapy” NCT07715630 ↗ |
| Route | Intravenous | “Eligible subjects will be treated with PICX Injection as a single intravenous infusion.” NCT07715630 ↗ |